Aduro Biotech Inc. (NASDAQ:ADRO) saw an uptick in trading volume on Monday . 417,981 shares were traded during trading, an increase of 26% from the previous session’s volume of 332,760 shares.The stock last traded at $15.74 and had previously closed at $15.55.

Several research firms have recently commented on ADRO. FBR & Co restated a “buy” rating and set a $34.00 price target (up previously from $30.00) on shares of Aduro Biotech in a research note on Saturday, May 14th. Canaccord Genuity restated a “buy” rating on shares of Aduro Biotech in a research note on Tuesday, May 3rd. Zacks Investment Research cut Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Leerink Swann restated a “buy” rating and set a $48.00 price target on shares of Aduro Biotech in a research note on Thursday, May 5th. Finally, Roth Capital restated a “buy” rating and set a $22.00 price target (down previously from $46.00) on shares of Aduro Biotech in a research note on Monday, May 16th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Aduro Biotech currently has a consensus rating of “Hold” and an average price target of $22.00.

The stock’s market cap is $1.01 billion. The firm’s 50 day moving average is $12.93 and its 200-day moving average is $13.25.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.21. The firm earned $39 million during the quarter, compared to analyst estimates of $25.24 million. The company’s revenue for the quarter was up 306.3% on a year-over-year basis. On average, equities research analysts forecast that Aduro Biotech Inc. will post ($1.17) EPS for the current fiscal year.

In other news, insider Thomas W. Dubensky sold 25,000 shares of Aduro Biotech stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total value of $290,250.00. Following the completion of the transaction, the insider now owns 13,939 shares in the company, valued at approximately $161,831.79. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC increased its position in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned about 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.